Paroxetine low-dose - Noven Therapeutics

Drug Profile

Paroxetine low-dose - Noven Therapeutics

Alternative Names: Brisdelle; LDMP; Low-dose mesylate salt of paroxetine; Mesafem; Paroxetine mesylate

Latest Information Update: 16 Oct 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synthon Pharmaceuticals Ltd
  • Developer Noven Therapeutics
  • Class Antidepressants; Anxiolytics; Benzodioxoles; Fluorobenzenes; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Vasomotor symptoms

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Oct 2014 Adverse events data from two phase III studies in Vasomotor symptoms released by Noven Pharmaceuticals
  • 13 Jan 2014 Noven Pharmaceuticals and Shionogi agree to co-promote low-dose paroxetine in USA for Vasomotor symptoms
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top